证券日报网讯 8月14日晚间，海森药业发布公告称，公司第三届董事会第十四次会议审议通过了《关于 公司2025年半年度报告全文及摘要的议案》等多项议案。 （文章来源：证券日报） ...

（文章来源：证券日报） 证券日报网讯 8月14日晚间，海森药业发布公告称，公司第三届监事会第十三次会议审议通过了《关于 公司2025年半年度报告全文及摘要的议案》等多项议案。 ...

证券日报网讯 8月14日晚间，海森药业发布2025年半年度报告摘要称，公司2025年半年度实现营业收入 为242，085，860.34元，同比增长14.93%；实现归属于上市公司股东的净利润为60，794，153.31元， 同比增长4.74%。 （文章来源：证券日报） ...

Core Viewpoint - Haosen Pharmaceutical reported strong financial performance for the first half of 2025, achieving record revenue and profit levels since its listing, driven by robust market demand and effective production optimization [2][3]. Financial Performance - The company achieved operating revenue of 242 million yuan, a year-on-year increase of 14.93% [2]. - Net profit attributable to shareholders reached 60.79 million yuan, up 4.74% year-on-year [2]. - Deducting non-recurring gains and losses, the net profit was 59.25 million yuan, reflecting a growth of 4.82% [2]. Market Dynamics - Haosen Pharmaceutical experienced strong order volumes for its main products, indicating a favorable supply-demand balance [2]. - The company reported a significant increase in overseas sales, which rose by 53.04% year-on-year, highlighting successful international market expansion [2]. Research and Development - R&D investment amounted to 17.71 million yuan, representing 7.32% of operating revenue, with a year-on-year increase of 52.83% [2]. - The company is actively pursuing diverse channels for R&D成果转化, aiming to convert research outcomes into market value [2]. - As of the reporting period, there are 17 products under development, including APIs and intermediates targeting various therapeutic areas [2]. Strategic Initiatives - Haosen Pharmaceutical signed an investment cooperation agreement with the Dongyang Economic Development Zone to establish a new production facility [3]. - The new facility will include a project for the annual production of 300 tons of A-40 (Atorvastatin Calcium) [3]. - The company's R&D center and office building are expected to be operational by the end of September 2025, enhancing its R&D capabilities and production capacity [3].

（文章来源：证券日报） 证券日报网讯 8月14日晚间，海森药业发布公告称，董事会同意聘任吴洋宽先生为公司副总经理。 ...

海森药业（SZ 001367，收盘价：25.86元）8月14日晚间发布半年度业绩报告称，2025年上半年营业收 入约2.42亿元，同比增加14.93%；归属于上市公司股东的净利润约6079万元，同比增加4.74%；基本每 股收益0.41元，同比增加5.13%。 （文章来源：每日经济新闻） ...

海森药业（SZ 001367，收盘价：25.86元）8月14日晚间发布公告称，公司审议通过《关于聘任吴洋宽 为公司副总经理的议案》。结合公司经营发展需要，经公司总经理艾林先生提名，董事会提名委员会审 议通过，董事会同意聘任吴洋宽先生为公司副总经理。 （文章来源：每日经济新闻） 2024年1至12月份，海森药业的营业收入构成为：医药制造业占比100.0%。 ...

浙江海森药业股份有限公司 2025 年半年 度报告摘要 证券代码：001367 证券简称：海森药 业 公告编号：2025-031 会指定媒体仔细阅读半年度报告全文。 所有董事均已出席了审议本报告的董事会会议。 非标准审计意见提示 □适用 ? 不适用 董事会审议的报告期利润分配预案或公积金转增股本预案 □适用 ? 不适用 公司计划不派发现金红利，不送红股，不以公积金转增股本。 董事会决议通过的本报告期优先股利润分配预案 浙江海森药业股份有限公司 2025 年半年度报告摘要 一、重要提示 本半年度报告摘要来自半年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投 资者应当到证监 电话 0579-86768756 0579-86768756 电子信箱 hsxp@zjhaisen.com hsxp@zjhaisen.com □适用 ? 不适用 二、公司基本情况 股票简称 海森药业 股票代码 001367 股票上市交易所 深圳证券交易所 变更前的股票简称（如有） 无 联系人和联系方式 董事会秘书 证券事 务代表 姓名 胡康康 滕芳 办公地址 浙江省东阳市六石街道香潭村 浙江省东阳市六 本报告期比上 本报 ...

Core Viewpoint - Zhejiang Haisen Pharmaceutical Co., Ltd. reported a revenue increase of 14.93% in the first half of 2025, driven by strong market demand and effective sales strategies [12][22]. Financial Performance - The company achieved operating revenue of 242.09 million yuan, compared to 210.64 million yuan in the same period last year [10]. - Net profit attributable to shareholders was 59.25 million yuan, reflecting a 4.74% increase year-on-year [12]. - The basic earnings per share rose to 0.41 yuan, up 5.13% from the previous year [10]. Industry Overview - The pharmaceutical manufacturing industry is experiencing growth due to factors such as population aging, urbanization, and improved healthcare systems [9]. - The global pharmaceutical market is projected to reach 3.57 trillion doses by 2025, with China expected to lead in growth with a compound annual growth rate of 1.6% [9]. - The chemical raw materials industry is a strategic pillar of China's pharmaceutical sector, with a market size expected to exceed 740 billion yuan by 2029 [10]. Business Operations - The company specializes in the research, production, and sales of chemical pharmaceutical raw materials and intermediates, focusing on digestive, cardiovascular, and antibacterial drugs [11][19]. - The product portfolio includes high-demand items such as sucralfate and atorvastatin calcium, which have significant market shares [19][20]. - The company employs a direct sales model, ensuring close relationships with manufacturers and traders [17]. Market Position - The company is a leading manufacturer of sucralfate and atorvastatin calcium, with a strong competitive edge in both domestic and international markets [19][20]. - The company has established long-term partnerships with global clients, enhancing its market presence [21]. Research and Development - The company invested 1.77 million yuan in R&D, accounting for 7.32% of its revenue, indicating a commitment to innovation [23]. - The company has a robust pipeline of new products, with ongoing projects aimed at enhancing market competitiveness [23][24]. - A total of 25 patents have been obtained, covering various aspects of pharmaceutical production [26]. Quality Management - The company adheres to international GMP standards, ensuring high-quality production processes [27]. - A laboratory information management system (LIMS) has been implemented to enhance quality control and data integrity [27].

证券代码：001367 证券简称：海森药业 公告编号：2025-036 浙江海森药业股份有限公司（以下简称"公司"）于2025年8月2日以电子 邮件及电话通知的方式向全体董事发出了关于召开第三届董事会第十四次会议 的通知，会议于2025年8月13日在公司会议室以现场方式召开。本次会议由董事 长王式跃先生主持，应出席董事7名，实际出席董事7名。公司监事、高级管理 人员列席了本次会议。本次会议的召集和召开符合《公司法》《公司章程》等 有关规定，会议合法、有效。 二、董事会会议审议情况 《2025年半年度报告》和《2025年半年度报告摘要》内容真实、准确、完 整地反映了公司2025年半年度的经营状况和财务信息。 本议案已经公司第三届董事会审计委员会第十三次会议审议通过，并同意提 交董事会审议。 具体内容详见公司同日刊登在《证券时报》《证券日报》《上海证券报》 和巨潮资讯网（www.cninfo.com.cn）上的《2025年半年度报告摘要》（公告编 号：2025-031）和在巨潮资讯网（www.cninfo.com.cn）上的《2025年半年度报 告》。 浙江海森药业股份有限公司 第三届董事会第十四次会议决议公告 ...